S&P 500   3,781.52 (-0.37%)
DOW   30,912.58 (-0.25%)
QQQ   313.45 (-0.29%)
AAPL   128.86 (-0.04%)
MSFT   213.95 (+0.44%)
FB   252.30 (+2.71%)
GOOGL   1,740.00 (+0.52%)
AMZN   3,113.00 (-0.46%)
TSLA   840.71 (-0.51%)
NVDA   522.25 (-1.09%)
BABA   245.00 (+0.83%)
CGC   33.73 (-2.57%)
GE   11.50 (-1.37%)
MU   81.53 (+0.28%)
AMD   89.70 (-1.20%)
T   29.16 (-0.44%)
NIO   57.18 (-6.06%)
F   9.94 (-2.26%)
ACB   12.08 (+1.00%)
BA   206.90 (-1.43%)
DIS   171.15 (-1.31%)
NFLX   501.94 (+0.22%)
GILD   63.50 (+1.76%)
S&P 500   3,781.52 (-0.37%)
DOW   30,912.58 (-0.25%)
QQQ   313.45 (-0.29%)
AAPL   128.86 (-0.04%)
MSFT   213.95 (+0.44%)
FB   252.30 (+2.71%)
GOOGL   1,740.00 (+0.52%)
AMZN   3,113.00 (-0.46%)
TSLA   840.71 (-0.51%)
NVDA   522.25 (-1.09%)
BABA   245.00 (+0.83%)
CGC   33.73 (-2.57%)
GE   11.50 (-1.37%)
MU   81.53 (+0.28%)
AMD   89.70 (-1.20%)
T   29.16 (-0.44%)
NIO   57.18 (-6.06%)
F   9.94 (-2.26%)
ACB   12.08 (+1.00%)
BA   206.90 (-1.43%)
DIS   171.15 (-1.31%)
NFLX   501.94 (+0.22%)
GILD   63.50 (+1.76%)
S&P 500   3,781.52 (-0.37%)
DOW   30,912.58 (-0.25%)
QQQ   313.45 (-0.29%)
AAPL   128.86 (-0.04%)
MSFT   213.95 (+0.44%)
FB   252.30 (+2.71%)
GOOGL   1,740.00 (+0.52%)
AMZN   3,113.00 (-0.46%)
TSLA   840.71 (-0.51%)
NVDA   522.25 (-1.09%)
BABA   245.00 (+0.83%)
CGC   33.73 (-2.57%)
GE   11.50 (-1.37%)
MU   81.53 (+0.28%)
AMD   89.70 (-1.20%)
T   29.16 (-0.44%)
NIO   57.18 (-6.06%)
F   9.94 (-2.26%)
ACB   12.08 (+1.00%)
BA   206.90 (-1.43%)
DIS   171.15 (-1.31%)
NFLX   501.94 (+0.22%)
GILD   63.50 (+1.76%)
S&P 500   3,781.52 (-0.37%)
DOW   30,912.58 (-0.25%)
QQQ   313.45 (-0.29%)
AAPL   128.86 (-0.04%)
MSFT   213.95 (+0.44%)
FB   252.30 (+2.71%)
GOOGL   1,740.00 (+0.52%)
AMZN   3,113.00 (-0.46%)
TSLA   840.71 (-0.51%)
NVDA   522.25 (-1.09%)
BABA   245.00 (+0.83%)
CGC   33.73 (-2.57%)
GE   11.50 (-1.37%)
MU   81.53 (+0.28%)
AMD   89.70 (-1.20%)
T   29.16 (-0.44%)
NIO   57.18 (-6.06%)
F   9.94 (-2.26%)
ACB   12.08 (+1.00%)
BA   206.90 (-1.43%)
DIS   171.15 (-1.31%)
NFLX   501.94 (+0.22%)
GILD   63.50 (+1.76%)
Log in
NASDAQ:RKDA

Arcadia Biosciences Competitors

$2.85
+0.03 (+1.06 %)
(As of 01/15/2021 12:53 PM ET)
Add
Compare
Today's Range
$2.82
Now: $2.85
$2.93
50-Day Range
$2.47
MA: $2.85
$3.34
52-Week Range
$2.30
Now: $2.85
$6.48
Volume1,363 shs
Average Volume503,546 shs
Market Capitalization$30.87 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.7

Competitors

Arcadia Biosciences (NASDAQ:RKDA) Vs. CTVA, FDP, VFF, AGRO, LND, and LMNR

Should you be buying RKDA stock or one of its competitors? Companies in the industry of "agricultural production - crops" are considered alternatives and competitors to Arcadia Biosciences, including Corteva (CTVA), Fresh Del Monte Produce (FDP), Village Farms International (VFF), Adecoagro (AGRO), BrasilAgro - Companhia Brasileira de Propriedades Agrícolas (LND), and Limoneira (LMNR).

Corteva (NYSE:CTVA) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Earnings and Valuation

This table compares Corteva and Arcadia Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corteva$13.85 billion2.34$-959,000,000.00$1.4330.45
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85

Arcadia Biosciences has lower revenue, but higher earnings than Corteva. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Corteva, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Corteva and Arcadia Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corteva371202.41
Arcadia Biosciences00203.00

Corteva presently has a consensus price target of $36.1667, suggesting a potential downside of 16.90%. Arcadia Biosciences has a consensus price target of $12.00, suggesting a potential upside of 321.05%. Given Arcadia Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Arcadia Biosciences is more favorable than Corteva.

Volatility and Risk

Corteva has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -0.7, indicating that its share price is 170% less volatile than the S&P 500.

Profitability

This table compares Corteva and Arcadia Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corteva4.42%4.70%2.72%
Arcadia Biosciences-1,973.82%-175.11%-60.58%

Insider and Institutional Ownership

77.2% of Corteva shares are owned by institutional investors. Comparatively, 4.9% of Arcadia Biosciences shares are owned by institutional investors. 0.2% of Corteva shares are owned by insiders. Comparatively, 3.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Corteva beats Arcadia Biosciences on 9 of the 14 factors compared between the two stocks.

Fresh Del Monte Produce (NYSE:FDP) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Fresh Del Monte Produce has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -0.7, indicating that its share price is 170% less volatile than the S&P 500.

Earnings and Valuation

This table compares Fresh Del Monte Produce and Arcadia Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresh Del Monte Produce$4.49 billion0.26$66.50 millionN/AN/A
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85

Fresh Del Monte Produce has higher revenue and earnings than Arcadia Biosciences.

Insider and Institutional Ownership

67.4% of Fresh Del Monte Produce shares are owned by institutional investors. Comparatively, 4.9% of Arcadia Biosciences shares are owned by institutional investors. 35.6% of Fresh Del Monte Produce shares are owned by insiders. Comparatively, 3.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Fresh Del Monte Produce and Arcadia Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresh Del Monte Produce0000N/A
Arcadia Biosciences00203.00

Arcadia Biosciences has a consensus price target of $12.00, suggesting a potential upside of 321.05%. Given Arcadia Biosciences' higher probable upside, analysts clearly believe Arcadia Biosciences is more favorable than Fresh Del Monte Produce.

Profitability

This table compares Fresh Del Monte Produce and Arcadia Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresh Del Monte Produce0.53%2.16%1.12%
Arcadia Biosciences-1,973.82%-175.11%-60.58%

Summary

Fresh Del Monte Produce beats Arcadia Biosciences on 9 of the 12 factors compared between the two stocks.

Village Farms International (NASDAQ:VFF) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Village Farms International has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500.

Valuation and Earnings

This table compares Village Farms International and Arcadia Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Village Farms International$144.57 million6.00$2.33 million$0.05259.20
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85

Village Farms International has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Village Farms International, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

14.8% of Village Farms International shares are owned by institutional investors. Comparatively, 4.9% of Arcadia Biosciences shares are owned by institutional investors. 20.4% of Village Farms International shares are owned by insiders. Comparatively, 3.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Village Farms International and Arcadia Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Village Farms International00313.25
Arcadia Biosciences00203.00

Village Farms International presently has a consensus price target of $13.40, suggesting a potential upside of 3.63%. Arcadia Biosciences has a consensus price target of $12.00, suggesting a potential upside of 321.05%. Given Arcadia Biosciences' higher probable upside, analysts plainly believe Arcadia Biosciences is more favorable than Village Farms International.

Profitability

This table compares Village Farms International and Arcadia Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Village Farms International-5.42%-9.65%-6.74%
Arcadia Biosciences-1,973.82%-175.11%-60.58%

Summary

Village Farms International beats Arcadia Biosciences on 12 of the 15 factors compared between the two stocks.

Adecoagro (NYSE:AGRO) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility and Risk

Adecoagro has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500.

Valuation and Earnings

This table compares Adecoagro and Arcadia Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adecoagro$887.14 million1.06$-770,000.00$0.3423.56
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85

Adecoagro has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Adecoagro, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

53.6% of Adecoagro shares are owned by institutional investors. Comparatively, 4.9% of Arcadia Biosciences shares are owned by institutional investors. 3.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Adecoagro and Arcadia Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Adecoagro00203.00
Arcadia Biosciences00203.00

Adecoagro presently has a consensus price target of $6.00, suggesting a potential downside of 25.00%. Arcadia Biosciences has a consensus price target of $12.00, suggesting a potential upside of 321.05%. Given Arcadia Biosciences' higher probable upside, analysts plainly believe Arcadia Biosciences is more favorable than Adecoagro.

Profitability

This table compares Adecoagro and Arcadia Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Adecoagro-4.53%10.33%4.01%
Arcadia Biosciences-1,973.82%-175.11%-60.58%

Summary

Adecoagro beats Arcadia Biosciences on 8 of the 12 factors compared between the two stocks.

BrasilAgro - Companhia Brasileira de Propriedades Agrícolas (NYSE:LND) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for BrasilAgro - Companhia Brasileira de Propriedades Agrícolas and Arcadia Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas0000N/A
Arcadia Biosciences00203.00

Arcadia Biosciences has a consensus price target of $12.00, suggesting a potential upside of 321.05%. Given Arcadia Biosciences' higher probable upside, analysts plainly believe Arcadia Biosciences is more favorable than BrasilAgro - Companhia Brasileira de Propriedades Agrícolas.

Volatility and Risk

BrasilAgro - Companhia Brasileira de Propriedades Agrícolas has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500.

Insider & Institutional Ownership

0.4% of BrasilAgro - Companhia Brasileira de Propriedades Agrícolas shares are owned by institutional investors. Comparatively, 4.9% of Arcadia Biosciences shares are owned by institutional investors. 0.7% of BrasilAgro - Companhia Brasileira de Propriedades Agrícolas shares are owned by insiders. Comparatively, 3.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares BrasilAgro - Companhia Brasileira de Propriedades Agrícolas and Arcadia Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas19.44%13.50%7.75%
Arcadia Biosciences-1,973.82%-175.11%-60.58%

Valuation and Earnings

This table compares BrasilAgro - Companhia Brasileira de Propriedades Agrícolas and Arcadia Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas$159.94 million2.05$26.73 millionN/AN/A
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85

BrasilAgro - Companhia Brasileira de Propriedades Agrícolas has higher revenue and earnings than Arcadia Biosciences.

Summary

BrasilAgro - Companhia Brasileira de Propriedades Agrícolas beats Arcadia Biosciences on 7 of the 12 factors compared between the two stocks.

Arcadia Biosciences (NASDAQ:RKDA) and Limoneira (NASDAQ:LMNR) are both small-cap basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Arcadia Biosciences and Limoneira, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcadia Biosciences00203.00
Limoneira01302.75

Arcadia Biosciences presently has a consensus target price of $12.00, suggesting a potential upside of 321.05%. Limoneira has a consensus target price of $18.20, suggesting a potential upside of 18.95%. Given Arcadia Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcadia Biosciences is more favorable than Limoneira.

Risk and Volatility

Arcadia Biosciences has a beta of -0.7, suggesting that its stock price is 170% less volatile than the S&P 500. Comparatively, Limoneira has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Insider & Institutional Ownership

4.9% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 52.9% of Limoneira shares are held by institutional investors. 3.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 3.9% of Limoneira shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Arcadia Biosciences and Limoneira's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcadia Biosciences-1,973.82%-175.11%-60.58%
Limoneira-7.05%-4.17%-2.20%

Earnings and Valuation

This table compares Arcadia Biosciences and Limoneira's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$1.17 million26.39$-28,810,000.00($3.37)-0.85
Limoneira$171.40 million1.60$-5,940,000.00($0.45)-34.27

Limoneira has higher revenue and earnings than Arcadia Biosciences. Limoneira is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Limoneira beats Arcadia Biosciences on 10 of the 14 factors compared between the two stocks.


Arcadia Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CTVA
Corteva
1.9$43.55+1.5%$32.94 billion$13.85 billion53.11Analyst Report
Fresh Del Monte Produce logo
FDP
Fresh Del Monte Produce
1.3$24.71+0.2%$1.17 billion$4.49 billion51.48
VFF
Village Farms International
1.3$12.96+10.7%$960.19 million$144.57 million-81.00Analyst Upgrade
Adecoagro logo
AGRO
Adecoagro
1.2$8.01+1.7%$921.47 million$887.14 million-25.03Analyst Upgrade
Heavy News Reporting
LND
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas
0.9$5.27+2.8%$336.60 million$159.94 million10.33Increase in Short Interest
Heavy News Reporting
Limoneira logo
LMNR
Limoneira
1.4$15.42+2.7%$282.03 million$171.40 million-21.42Earnings Announcement
Analyst Downgrade
Alico logo
ALCO
Alico
2.3$30.99+1.2%$235.31 million$92.51 million9.81Heavy News Reporting
S&W Seed logo
SANW
S&W Seed
2.1$3.75+0.5%$126.23 million$79.58 million-6.36Analyst Upgrade
SEED
Origin Agritech
0.6$18.25+1.6%$86.18 million$13.43 million0.00
TYHT
Shineco
0.6$3.50+5.1%$11.19 million$23.68 million-2.05Increase in Short Interest
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.